This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and low-toxic treatment strategy for non-small cell lung cancer (NSCLC) with multiple metastases. The main objective is to explore and compare the control rates of abscopal lesions in NSCLC patients with multiple metastases when different radiotherapy fractionation patterns are combined with Benmelstobart.
Non-small cell lung cancer confirmed by pathological histology.
More than 3 metastatic lesions.
No brain metastases or stable lesions.
Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET).
Those with severe dysfunction of important vital organs (heart, liver, kidney).
Those accompanied by other malignant tumors.
Uncontrolled heart diseases or myocardial infarction within the past 6 months.
Those with a history of mental illness.
6
Treatment groupsSee each treatment group below.